TABLE OF CONTENTS

Volume 86, Issue 6 (December 2009)

Top

In This Issue

Top

Editorial

Editorial

Neonatal Pharmacology: Rational Therapeutics for the Most Vulnerable

L James and S Ito

Clin Pharmacol Ther 86: 573-577; doi:10.1038/clpt.2009.212

Top

News & Views

Highlights

Highlights

Clin Pharmacol Ther 86: 578-579; doi:10.1038/clpt.2009.230

ASCPT News

ASCPT News

Clin Pharmacol Ther 86: 580-582; doi:10.1038/clpt.2009.220

Books

Pediatric Drug Development: Concepts and Applications

Reviewed by S M MacLeod

Clin Pharmacol Ther 86: 583-584; doi:10.1038/clpt.2009.192

Top

Perspectives

Opinion

Clinical Trials in Neonates: A Therapeutic Imperative FREE

R M Ward and S E Kern

Clin Pharmacol Ther 86: 585-587; doi:10.1038/clpt.2009.207

Can We Afford It?: Ethical Consideration of Expensive Drug Treatment for Neonates and Infants FREE

R Zlotnik Shaul and D Vitale

Clin Pharmacol Ther 86: 587-589; doi:10.1038/clpt.2009.211

Clinical Trial Design in Neonatal Pharmacology: Effect of Center Differences, With Lessons From the Pediatric Oncology Cooperative Research Experience FREE

C Moran, P B Smith, M Cohen-Wolkowiez and D K Benjamin Jr

Clin Pharmacol Ther 86: 589-591; doi:10.1038/clpt.2009.175

Commentaries

The Road From Discovery to Clinic: Adiponectin as a Biomarker of Metabolic Status

C M Kusminski and P E Scherer

Clin Pharmacol Ther 86: 592-595; doi:10.1038/clpt.2009.155

See also: Article by Wagner et al.
Current Understanding of the Pharmacogenomics of Metformin

O Zolk

Clin Pharmacol Ther 86: 595-598; doi:10.1038/clpt.2009.144

See also: Books by MacLeod

Letters to the Editor

Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?

B Renner and K Brune

Clin Pharmacol Ther 86: 599-600; advance online publication, May 6, 2009; doi:10.1038/clpt.2009.65

See also: Letter to the Editor by MooreSee also: Letter to the Editor by van Beers et al. See also: Letter to the Editor by Fosbøl et al.
No Obvious Extra Cardiovascular Risk Associated With Low-Dose NSAIDs

N Moore

Clin Pharmacol Ther 86: 600-601; advance online publication, May 6, 2009; doi:10.1038/clpt.2009.66

See also: Letter to the Editor by Renner & BruneSee also: Letter to the Editor by van Beers et al. See also: Letter to the Editor by Fosbøl et al.
Do NSAIDs Actually Protect Against Myocardial Infarction and Death?

E J van Beers, J R de Groot and J G P Tijssen

Clin Pharmacol Ther 86: 601-602; advance online publication, October 28, 2009; doi:10.1038/clpt.2009.164

See also: Letter to the Editor by Renner & BruneSee also: Letter to the Editor by MooreSee also: Letter to the Editor by Fosbøl et al.
Response to "No Obvious Extra Cardiovascular Risk Associated With Low-Dose NSAIDs," "Do NSAIDs Actually Protect Against Myocardial Infarction and Death?," and "Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?"

E L Fosbøl, G H Gislason, L Køber and C Torp-Pedersen

Clin Pharmacol Ther 86: 602-604; advance online publication, October 28, 2009; doi:10.1038/clpt.2009.204

See also: Letter to the Editor by Renner & BruneSee also: Letter to the Editor by MooreSee also: Letter to the Editor by van Beers et al.
Top

Research

Report

Genetic Influences on the Pharmacokinetics of Orally and Intravenously Administered Digoxin as Exhibited by Monozygotic Twins

A L Birkenfeld, J Jordan, U Hofmann, A Busjahn, G Franke, N Krüger, S Igel, T Mürdter, S Drescher, S Shi, S Engeli, M Schwab, M Eichelbaum, F C Luft and M F Fromm

Clin Pharmacol Ther 86: 605-608; advance online publication, September 23, 2009; doi:10.1038/clpt.2009.170

Articles

Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients

W Zhao, V Elie, G Roussey, K Brochard, P Niaudet, V Leroy, C Loirat, P Cochat, S Cloarec, J L André, F Garaix, A Bensman, M Fakhoury and E Jacqz-Aigrain

Clin Pharmacol Ther 86: 609-618; advance online publication, October 28, 2009; doi:10.1038/clpt.2009.210

Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors

J A Wagner, E C Wright, M M Ennis, M Prince, J Kochan, D J R Nunez, B Schneider, M-D Wang, Y Chen, S Ghosh, B J Musser and M T Vassileva

Clin Pharmacol Ther 86: 619-625; advance online publication, June 24, 2009; doi:10.1038/clpt.2009.88

See also: Commentary by Kusminski & Scherer
Escitalopram Is a Weak Inhibitor of the CYP2D6-Catalyzed O-Demethylation of (+)-Tramadol but Does Not Reduce the Hypoalgesic Effect in Experimental Pain

L Noehr-Jensen, S T Zwisler, F Larsen, S H Sindrup, P Damkier and K Brosen

Clin Pharmacol Ther 86: 626-633; advance online publication, August 26, 2009; doi:10.1038/clpt.2009.154

Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study FREE

S Willmann, A N Edginton, K Coboeken, G Ahr and J Lippert

Clin Pharmacol Ther 86: 634-643; advance online publication, August 26, 2009; doi:10.1038/clpt.2009.151

Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects

R E Steinert, B Poller, M C Castelli, K Friedman, A R Huber, J Drewe and C Beglinger

Clin Pharmacol Ther 86: 644-650; advance online publication, September 2, 2009; doi:10.1038/clpt.2009.159

Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia FREE

J C Panetta, A Gajjar, N Hijiya, L J Hak, C Cheng, W Liu, C H Pui and M V Relling

Clin Pharmacol Ther 86: 651-658; advance online publication, September 9, 2009; doi:10.1038/clpt.2009.162

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

R Krishna, B Gumbiner, C Stevens, B Musser, M Mallick, S Suryawanshi, L Maganti, H Zhu, T H Han, L Scherer, B Simpson, D Cosgrove, K Gottesdiener, J Amatruda, B J Rolls, J Blundell, G A Bray, K Fujioka, S B Heymsfield, J A Wagner and G A Herman

Clin Pharmacol Ther 86: 659-666; advance online publication, September 9, 2009; doi:10.1038/clpt.2009.167

Top

Discovery & Development

Discovery

Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-Like Peptide-2 Analog in Neonates and Infants With Short-Bowel Syndrome

M S Mouksassi, J F Marier, J Cyran and A A Vinks

Clin Pharmacol Ther 86: 667-671; advance online publication, October 21, 2009; doi:10.1038/clpt.2009.199

Development

Sustained Neurobehavioral Effects of Exposure to SSRI Antidepressants During Development: Molecular to Clinical Evidence

T F Oberlander, J A Gingrich and M S Ansorge

Clin Pharmacol Ther 86: 672-677; advance online publication, November 4, 2009; doi:10.1038/clpt.2009.201

Developmental Pharmacogenetics: A General Paradigm for Application to Neonatal Pharmacology and Toxicology FREE

J S Leeder

Clin Pharmacol Ther 86: 678-682; advance online publication, October 28, 2009; doi:10.1038/clpt.2009.195

Top

Erratum & Corrigendum

Erratum & Corrigendum

ERRATUM: The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies

Clin Pharmacol Ther 86: 683; doi:10.1038/clpt.2009.174

CORRIGENDUM: Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease

Clin Pharmacol Ther 86: 683; doi:10.1038/clpt.2009.180

Extra navigation

.

naturejobs

ADVERTISEMENT